Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Payables: 2019-2024

Historic Payables for Eton Pharmaceuticals (ETON) over the last 6 years, with Dec 2024 value amounting to $4.2 million.

  • Eton Pharmaceuticals' Payables rose 431.26% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.4 million, marking a year-over-year increase of 296.95%. This contributed to the annual value of $4.2 million for FY2024, which is 125.49% up from last year.
  • As of FY2024, Eton Pharmaceuticals' Payables stood at $4.2 million, which was up 125.49% from $1.8 million recorded in FY2023.
  • In the past 5 years, Eton Pharmaceuticals' Payables ranged from a high of $4.2 million in FY2024 and a low of $1.8 million during FY2022.
  • Its 3-year average for Payables is $2.6 million, with a median of $1.8 million in 2023.
  • Per our database at Business Quant, Eton Pharmaceuticals' Payables surged by 307.65% in 2020 and then decreased by 24.32% in 2021.
  • Eton Pharmaceuticals' Payables (MRY) stood at $2.3 million in 2020, then dropped by 24.32% to $1.8 million in 2021, then fell by 0.45% to $1.8 million in 2022, then grew by 4.64% to $1.8 million in 2023, then skyrocketed by 125.49% to $4.2 million in 2024.
  • Its last three reported values are $4.2 million in FY2024, $1.8 million for FY2023, and $1.8 million during FY2022.